États financiers détaillés de Femasys Inc. (FEMY): compte de résultat, bilan et tableau de flux de trésorerie. Suivez l'évolution des marges, de la dette, de la liquidité et de la rentabilité d'une année sur l'autre avec jusqu'à 20 ans d'historique.
Résumé de l'Analyse
Femasys Inc. a enregistré un chiffre d'affaires de $2.3M sur le dernier exercice, avec un CAGR sur 5 ans de 17.2%.
Compte de Résultat (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenus | $929064 | $1.0M | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Coût des Ventes | $223678 | $306533 | $370384 | $441938 | $380069 | $544903 | $872400 |
| Marge Brute | $705386 | $731385 | $809305 | $764280 | $691901 | $1.1M | $1.4M |
| R&D | $6.9M | $4.1M | $4.1M | $5.8M | $7.2M | $8.2M | $7.6M |
| Frais Généraux | $4.8M | $2.9M | $4.5M | $6.0M | $7.5M | $10.4M | $11.1M |
| Charges Opérationnelles | $12.3M | $7.7M | $9.1M | $12.4M | $15.2M | $18.9M | $19.0M |
| Résultat Opérationnel | -$11.6M | -$6.9M | -$8.3M | -$11.6M | -$14.5M | -$17.8M | -$17.6M |
| EBITDA | -$10.2M | -$5.8M | -$6.6M | -$10.5M | -$13.2M | -$16.3M | -$15.9M |
| Charges d'Intérêt | $9972 | $12553 | $19226 | $13464 | $165390 | $1.6M | $1.9M |
| Résultat Avant Impôts | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Impôts | $3006 | $1800 | $4000 | $6300 | $4338 | $9602 | $1297 |
| Résultat Net | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| BPA | $-19.20 | $-11.80 | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| BPA Dilué | $-19.20 | $-11.80 | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| Actions en Circulation (Diluées) | $588078 | $588078 | $590208 | $590208 | $769219 | $1.1M | $2.0M |
Bilan (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Trésorerie | $6.4M | $3.3M | $24.8M | $13.0M | $21.7M | $3.5M | $9.3M |
| Placements à Court Terme | $998831 | 0 | 0 | 0 | 0 | 0 | 0 |
| Créances | $83554 | $125790 | $84258 | $77470 | $98906 | $488373 | $616600 |
| Stocks | $172497 | $131378 | $208270 | $436723 | $667118 | $3.0M | $5.7M |
| Actifs Courants | $8.0M | $3.9M | $25.6M | $14.1M | $23.2M | $8.0M | $16.5M |
| Immobilisations Corporelles | $3.9M | $2.9M | $2.3M | $1.8M | $3.5M | $3.4M | $3.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | $160592 | $65069 | $25093 | $3294 | 0 | $65918 | $134914 |
| Actifs Totaux | $12.6M | $7.6M | $28.6M | $16.9M | $27.8M | $12.4M | $20.7M |
| Dettes Fournisseurs | $481099 | $674333 | $445522 | $510758 | $1.1M | $1.4M | $1.8M |
| Dette à Court Terme | 0 | $630010 | $181123 | $141298 | 0 | $5.4M | 0 |
| Passifs Courants | $1.3M | $2.9M | $1.7M | $1.5M | $3.1M | $8.6M | $3.6M |
| Dette à Long Terme | 0 | $182490 | 0 | 0 | $4.3M | 0 | $3.2M |
| Passifs Totaux | $58.0M | $4.1M | $2.2M | $1.7M | $9.4M | $10.1M | $14.9M |
| Réserves | -$68.3M | -$75.2M | -$82.7M | -$94.1M | -$108.4M | -$127.2M | -$145.8M |
| Capitaux Propres | -$45.4M | $3.5M | $26.3M | $15.2M | $18.4M | $2.3M | $5.9M |
| Dette Totale | $1.7M | $2.1M | $990214 | $543715 | $6.7M | $7.4M | $4.7M |
| Dette Nette | -$5.7M | -$1.3M | -$23.8M | -$12.4M | -$15.0M | $4.0M | -$4.6M |
| Fonds de Roulement | $6.8M | $974598 | $23.9M | $12.6M | $20.1M | -$560420 | $12.8M |
Tableau de Flux (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Résultat Net | -$11.3M | -$6.9M | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| Amortissements | $1.1M | $1.1M | $964287 | $889140 | $907985 | $872000 | $804281 |
| Stock-based Compensation | $358841 | $318640 | $193366 | $224939 | $675700 | $444147 | $790145 |
| Variation du BFR | -$1.1M | $557962 | -$732716 | -$458267 | $1.2M | -$3.1M | -$2.1M |
| Cash Flow Opérationnel | -$11.0M | -$4.9M | -$7.9M | -$10.7M | -$11.3M | -$19.4M | -$18.7M |
| CapEx | -$696499 | -$31681 | -$306868 | -$407475 | -$143917 | -$761706 | -$525007 |
| Acquisitions | $103141 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rachat d'Actions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendes Payés | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$11.7M | -$5.0M | -$8.2M | -$11.1M | -$11.4M | -$20.2M | -$19.2M |
Croissance et Marges (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Croissance Revenus (annuelle) | +11.7% | +13.7% | +2.2% | -11.1% | +52.0% | +40.8% | |
| Croissance Résultat Net (annuelle) | +38.7% | -9.0% | -51.2% | -25.0% | -32.1% | +1.0% | |
| Croissance BPA (annuelle) | +38.5% | -8.5% | -51.6% | +4.1% | +9.7% | +44.0% | |
| Variation Actions (annuelle) | +0.0% | +0.4% | +0.0% | +30.3% | +44.7% | +77.6% | |
| Croissance FCF (annuelle) | +57.6% | -65.9% | -35.2% | -2.6% | -76.9% | +4.9% | |
| Marge Brute | 75.9% | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| Marge Opérationnelle | -1252.6% | -668.0% | -706.7% | -961.7% | -1353.4% | -1091.8% | -767.0% |
| Marge EBITDA | -1094.0% | -558.8% | -555.3% | -869.3% | -1228.5% | -1002.5% | -692.7% |
| Marge Nette | -1213.3% | -666.2% | -639.0% | -944.6% | -1329.1% | -1155.0% | -812.3% |
| Marge FCF | -1259.6% | -478.3% | -698.3% | -923.5% | -1065.7% | -1240.3% | -837.9% |
| Taux d'Imposition Effectif | -0.0% | -0.0% | -0.1% | -0.1% | -0.0% | -0.1% | -0.0% |
Données par Action (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF par Action | $-19.90 | $-8.44 | $-13.96 | $-18.87 | $-14.85 | $-18.15 | $-9.72 |
| Dividende par Action | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Actions en Circulation (Basiques) | $588078 | $588078 | $590208 | $590208 | $769219 | $1.1M | $2.0M |
Quoi regarder en Santé / Pharma
Le pipeline R&D est l'actif invisible. Brevets qui expirent = revenus qui s'évaporent. Regardez innovation et cash flow.
- R&D / Revenus — Indique l'investissement en pipeline futur. La pharma sérieuse réinvestit 15-20%
- Croissance EPS 5 ans — Après l'expiration des brevets, croissent-ils encore ?
- Marge brute — Pharma de marque >70%. Génériques bien plus bas — définit le type de business
- FCF / Net Income — Qualité du bénéfice — la grande pharma devrait convertir >90%
- ROIC — Capital réinvesti efficacement — clé en pharma à cause des cycles R&D longs
- Dette nette / EBITDA — Les acquisitions pharma génèrent beaucoup de dette — attention au post-M&A
- P/E vs 10 ans propre — La meilleure comparaison est avec son propre historique, pas avec les pairs
Santé financière
| Piotroski F-Score | 3 |
| Altman Z-Score | -10.88 |
Ratios Clés (10 ans)
| Année | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| PER | -12.50 | -20.34 | -6.09 | -0.93 | -1.05 | -1.31 | -1.23 |
| P/B | -3.11 | 40.01 | 1.75 | 0.70 | 0.82 | 10.63 | 3.88 |
| P/V | 151.91 | 135.98 | 39.02 | 8.81 | 13.99 | 15.04 | 9.93 |
| Marge Brute | 75.9% | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% |
| Marge Opérationnelle | -1252.6% | -668.0% | -706.7% | -961.7% | -1353.4% | -1091.8% | -767.0% |
| Marge Nette | -1213.3% | -666.2% | -639.0% | -944.6% | -1329.1% | -1155.0% | -812.3% |
Entreprises liées: AIMD · APLM · BCTX · COCH · CRIS · DARE · EKSO
Explorer le secteur: Healthcare · Medical - Instruments & Supplies
Plus de sections de FEMY: Vue d'ensemble · Valorisation · Statistiques · Estimations · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions